<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593004</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00620</org_study_id>
    <nct_id>NCT04593004</nct_id>
  </id_info>
  <brief_title>Teledermatology vs. Face-to-Face Visits in the Follow-Up of Patients With Acne</brief_title>
  <official_title>Randomized Open-Label Trial Comparing Teledermatology vs. Face-to-Face Consultation in the Follow-Up of Patients With Mild-to-Moderate Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acne vulgaris is a common cutaneous inflammatory condition of sebaceous follicles that can&#xD;
      profoundly affect patients' quality of life, especially at a young age. In this context the&#xD;
      use of teledermatology can potentially reduce the healthcare costs associated to traditional&#xD;
      consultations as well as the costs related to travel and loss of school/working time for the&#xD;
      patient, with a clear benefit for the whole community. Since 2016, the Department of&#xD;
      Dermatology at Inselspital Hospital in Bern has a portal and a smartphone app for online&#xD;
      advice service.&#xD;
&#xD;
      Hereby the investigators propose to explicitly investigate the efficacy of this system in&#xD;
      reducing healthcare costs as compared to traditional face-to-face consultations, in a cohort&#xD;
      of patients with mild-to-moderate acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 stratified random allocation</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total time spent by dermatologist after baseline</measure>
    <time_frame>4 months</time_frame>
    <description>Total cumulative time spent by dermatologist for face-to-face consultations or online assessments after baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total time spent by patient after baseline</measure>
    <time_frame>4 months</time_frame>
    <description>Total cumulative time spent by patient for visit-related travels and/or online procedures after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acne severity improvement</measure>
    <time_frame>2, 4 and 6 months</time_frame>
    <description>Acne severity improvement from baseline as assessed by 5-point ordinal investigator's global assessment (IGA) scale, ranging from 1 to 5, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of therapies prescribed for acne</measure>
    <time_frame>2, 4 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient study satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Overall patient satisfaction regarding the service received during the study as assessed by 11-point anchored visual analogue scale (VAS), ranging from 0 to 10, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Patient quality of life improvement from baseline as assessed by dermatology life quality index (DLQI), ranging from 0 to 30, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Teledermatology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Face-to-face consultation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Teledermatology</intervention_name>
    <description>Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - EvitaÂ® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.</description>
    <arm_group_label>Teledermatology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Face-to-face consultation</intervention_name>
    <description>Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.</description>
    <arm_group_label>Face-to-face consultation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Given written informed consent&#xD;
&#xD;
          -  Mild-to-moderate acne as assessed by IGA scale&#xD;
&#xD;
          -  Willingness and ability to adhere the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for systemic therapy for acne with Isotretinoin&#xD;
&#xD;
          -  Inability to use the teledermatology system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hunger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristine Heidemeyer, MD</last_name>
    <phone>316322218</phone>
    <phone_ext>+41</phone_ext>
    <email>Kristine.Heidemeyer@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of dermatology, University Hospital Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Heidemeyer, MD</last_name>
      <phone>316322218</phone>
      <phone_ext>+41</phone_ext>
      <email>Kristine.Heidemeyer@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>telemedicine</keyword>
  <keyword>teledermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

